Global Antibiotics Market Outlook, 2031

The global antibiotics industry covers medicines that kill or inhibit bacteria, used to treat infections of the respiratory tract, urinary tract, skin, bloodstream, abdomen, bones and joints, and sexually transmitted infections, and to prevent infections during surgery and cancer treatment. Major classes include penicillins, cephalosporins, carbapenems, macrolides, fluoroquinolones, tetracyclines, aminoglycosides, glycopeptides, oxazolidinones, sulfonamides and newer beta-lactam and beta-lactamase inhibitor combinations. Most antibiotics are off-patent and supplied by generic manufacturers such as Sandoz, Viatris, Teva, Aurobindo, Lupin, Cipla, Sun Pharma, Fresenius Kabi, Hikma and Chinese producers including CSPC, Kelun and North China Pharmaceutical, which also dominate global production of key active ingredients. Innovative antibiotics are developed by a small number of large companies, including Pfizer, Merck, GSK, Shionogi, AbbVie and Roche, and by specialist companies such as Innoviva Specialty Therapeutics, Venatorx, Basilea, Iterum, Paratek, Melinta, Entasis and Bugworks, often supported by public and philanthropic funders such as CARB-X, BARDA, the AMR Action Fund, GARDP and the Wellcome Trust. Antibiotics are among the most widely used medicines in the world, but the market is shaped by the paradox that new drugs must be used sparingly to slow resistance, limiting sales and deterring investment. Antimicrobial resistance has become one of the most serious global health threats. A study published in The Lancet in September 2024 estimated that resistant infections directly caused more than one million deaths a year and projected almost 40 million deaths between 2025 and 2050 without action. In the same month, the UN General Assembly adopted a political declaration committing countries to reduce deaths from antimicrobial resistance by 10% by 2030. The pandemic added pressure, as antibiotic use rose among COVID-19 patients and drug-resistant infections increased in hospitals. Supply problems have also been prominent, with shortages of amoxicillin and other common antibiotics in Europe and the United States during winter 2022 and 2023, highlighting dependence on a few low-cost producers. Policy makers have experimented with new payment models; the UK expanded its subscription scheme in 2024, paying fixed annual fees for access to selected new antibiotics regardless of volume, while the proposed US PASTEUR Act has not yet passed. New approvals have nonetheless continued, including Blujepa (gepotidacin), GSK's first-in-class oral antibiotic for urinary tract infections approved in March 2025, cefepime-enmetazobactam, ceftobiprole, sulopenem and aztreonam-avibactam, and in December 2025 the FDA approved both gepotidacin and zoliflodacin, the first new oral treatments for gonorrhoea in decades. Market Dynamics Market Drivers • High Burden of Bacterial InfectionsBacterial infections remain a leading cause of illness and death worldwide, including pneumonia, sepsis, urinary tract infections, skin infections and diarrhoeal diseases. Growing elderly populations, more surgery, cancer treatment, organ transplants and chronic diseases such as diabetes increase the number of patients at risk. In low- and middle-income countries, poor sanitation and limited vaccination add to the burden, supporting sustained demand for both generic and innovative antibiotics. • Rising Antimicrobial Resistance and Demand for New AgentsResistance to carbapenems, cephalosporins and fluoroquinolones among bacteria such as Klebsiella pneumoniae, Escherichia coli, Acinetobacter baumannii and Pseudomonas aeruginosa limits treatment options. Hospitals need new agents effective against these pathogens, supporting demand for novel beta-lactam combinations and first-in-class drugs. Governments and global health organisations have increased funding for antibiotic research and stewardship, and some countries have introduced incentives such as subscription payments. Market Challenges • Weak Commercial Returns for New AntibioticsNew antibiotics are typically held in reserve for resistant infections and used for short courses, resulting in low sales that rarely cover development costs. Several companies, including Achaogen and Melinta, went bankrupt or restructured after launching new antibiotics, and many large pharmaceutical companies have left the field. Without pull incentives such as subscription models or market entry rewards, investors remain reluctant to fund antibiotic development, leaving the pipeline thin. • Supply Chain Fragility and Generic Price PressureGeneric antibiotics are sold at very low prices, and production of many active ingredients is concentrated in China and India. Low margins have driven manufacturers out of the market, making supply vulnerable to disruptions, quality problems and demand spikes. Shortages of amoxicillin, penicillin G benzathine and other antibiotics have occurred in recent years, prompting governments to consider stockpiling, domestic manufacturing incentives and procurement reforms. Market Trends • Pull Incentives and Subscription Payment ModelsGovernments are testing ways to reward antibiotic innovation independently of sales volumes. The UK's subscription model, run by NICE and NHS England, pays fixed annual fees for selected antibiotics and was expanded in 2024. Japan and Canada have piloted revenue guarantees, and the EU has discussed transferable exclusivity vouchers. In the United States, the PASTEUR Act has been repeatedly proposed. Such models aim to make antibiotic development commercially viable while supporting stewardship. • New Mechanisms and Non-Traditional ApproachesDevelopers are advancing antibiotics with new mechanisms, such as gepotidacin and zoliflodacin, which inhibit bacterial topoisomerase in novel ways, and Roche's zosurabalpin, which targets Acinetobacter lipopolysaccharide transport. Non-traditional approaches, including bacteriophages, monoclonal antibodies, microbiome therapies, antivirulence agents and AI-discovered compounds, are also in development. Rapid diagnostics that identify pathogens and resistance quickly help doctors use targeted antibiotics. Segment Analysis Beta-lactam antibiotics, including penicillins, cephalosporins and carbapenems, account for the largest share of antibiotic use and value, while novel beta-lactam and beta-lactamase inhibitor combinations are the fastest-growing branded segment. Penicillins, such as amoxicillin and amoxicillin-clavulanate, are the most widely prescribed antibiotics globally, used for respiratory, ear, dental and skin infections, especially in children. Cephalosporins, including ceftriaxone, cefazolin, cefuroxime and cefixime, are used across hospital and community settings, with ceftriaxone a mainstay for serious infections and gonorrhoea. Carbapenems, including meropenem and imipenem, are reserved for serious hospital infections, and resistance to them is a major concern. Beta-lactam and beta-lactamase inhibitor combinations, such as ceftazidime-avibactam, meropenem-vaborbactam, imipenem-relebactam, ceftolozane-tazobactam, cefepime-enmetazobactam and aztreonam-avibactam, target resistant Gram-negative bacteria and command high prices. Macrolides, including azithromycin and clarithromycin, are widely used for respiratory infections. Fluoroquinolones, such as levofloxacin and ciprofloxacin, are used for urinary and respiratory infections, although safety warnings have reduced use. Tetracyclines, including doxycycline and newer omadacycline, treat respiratory, skin and sexually transmitted infections. Aminoglycosides, glycopeptides such as vancomycin, oxazolidinones such as linezolid, lipopeptides such as daptomycin and polymyxins such as colistin are important in hospital settings. New classes, including gepotidacin, a triazaacenaphthylene, and zoliflodacin, a spiropyrimidinetrione, represent the first new mechanisms for common infections in decades. Broad-spectrum antibiotics account for the largest share of use, while narrow-spectrum and targeted agents are growing in importance as stewardship programmes encourage more precise prescribing. Broad-spectrum antibiotics, which act against a wide range of Gram-positive and Gram-negative bacteria, are commonly used for empirical treatment when the cause of infection is unknown, particularly in hospitals and for severe infections such as sepsis. Examples include piperacillin-tazobactam, carbapenems, third-generation cephalosporins and fluoroquinolones. Their wide use contributes to resistance and to side effects such as Clostridioides difficile infection. Narrow-spectrum antibiotics target specific groups of bacteria and are preferred when the pathogen is known, reducing damage to the microbiome and selection pressure for resistance. The WHO AWaRe classification divides antibiotics into Access, Watch and Reserve groups and recommends that at least 70% of use should come from Access antibiotics, which are generally narrower in spectrum. Reserve antibiotics, including newer agents for multidrug-resistant infections, are meant to be used only when other options fail. Rapid diagnostics, including molecular tests and antimicrobial susceptibility tests, support the shift from broad to targeted therapy. Anti-Gram-negative agents are the main focus of innovation because of resistance in Enterobacterales, Acinetobacter and Pseudomonas, while anti-Gram-positive agents address MRSA and vancomycin-resistant enterococci. Respiratory tract infections account for the largest share of antibiotic prescriptions, while bloodstream infections, complicated intra-abdominal and urinary infections, and hospital-acquired pneumonia generate the highest value per patient. Respiratory tract infections, including community-acquired pneumonia, bronchitis, sinusitis, pharyngitis and otitis media, account for the largest number of antibiotic prescriptions, many of them in primary care, and a significant share are considered unnecessary because many respiratory infections are viral. Urinary tract infections are among the most common bacterial infections, especially in women, and rising resistance to trimethoprim-sulfamethoxazole and fluoroquinolones has created demand for new oral options such as gepotidacin and sulopenem. Skin and soft tissue infections, including cellulitis and infections caused by MRSA, are treated with a range of oral and intravenous antibiotics. Sexually transmitted infections, including gonorrhoea, chlamydia and syphilis, require specific antibiotics, and drug-resistant gonorrhoea has prompted development of zoliflodacin and gepotidacin. Bloodstream infections and sepsis require urgent intravenous treatment in hospitals. Complicated intra-abdominal infections and complicated urinary tract infections are key indications for new Gram-negative antibiotics. Hospital-acquired and ventilator-associated pneumonia, often caused by resistant bacteria, is treated with high-cost agents. Gastrointestinal infections, bone and joint infections, tuberculosis and surgical prophylaxis are additional segments, and Clostridioides difficile infection is treated with vancomycin, fidaxomicin and microbiome therapies. Hospital pharmacies account for the largest share of antibiotic value, driven by intravenous and branded agents, while retail pharmacies dispense the largest volume of oral antibiotics. Hospital pharmacies supply intravenous antibiotics for serious infections, surgical prophylaxis and intensive care, and they are the main channel for new branded agents targeting resistant bacteria. Hospital antimicrobial stewardship programmes, formularies and infectious disease specialists control which antibiotics are used, making hospital procurement central to the success of new drugs. Retail pharmacies dispense most oral antibiotics prescribed in primary care, including amoxicillin, azithromycin, doxycycline and nitrofurantoin, and account for the highest prescription volumes. In many low- and middle-income countries, antibiotics are sold without prescription in pharmacies and informal outlets, contributing to overuse. Online pharmacies and telehealth services have grown, particularly for urinary tract infections and sexually transmitted infections, although regulators are watching for inappropriate prescribing. Outpatient parenteral antibiotic therapy, delivered at home or in infusion centres, allows patients to complete intravenous treatment outside hospital. Long-term care facilities are major users of antibiotics for elderly residents. Government procurement and global health programmes, including tuberculosis programmes and GARDP's access initiatives, supply antibiotics in lower-income settings. Veterinary antibiotic use is regulated separately but affects resistance. Regional Analysis Asia-Pacific accounts for the largest volume of antibiotic consumption and production, while North America and Europe generate the highest value from branded and hospital antibiotics and lead in antibiotic innovation and stewardship policies. Asia-Pacific is the largest region for antibiotic consumption, driven by large populations in China, India, Indonesia and Pakistan, high rates of infectious diseases and widespread use of antibiotics in primary care, sometimes without prescription. China and India also dominate global production of antibiotic active ingredients and finished generics, with India a major exporter of generic antibiotics to Africa, Latin America and developed markets. Both countries face high levels of resistance and have launched national action plans, and India restricted over-the-counter sales of some antibiotics. Japan has a sizeable branded antibiotic market and has piloted pull incentives. North America, led by the United States, generates the highest value from branded antibiotics, particularly new agents for resistant hospital infections, and the FDA approved several new antibiotics between 2024 and 2025, including gepotidacin and zoliflodacin. The United States funds antibiotic development through BARDA and CARB-X, although the PASTEUR Act has not passed. Europe has strong stewardship programmes, especially in the Nordic countries and the Netherlands, and the UK's subscription model is a leading example of pull incentives. Europe experienced shortages of common antibiotics in 2022 and 2023, prompting EU measures to strengthen supply. Latin America, the Middle East and Africa have high infection burdens and growing resistance, with Africa facing some of the highest mortality from resistant infections and relying heavily on imported generics. Key Developments December 2025: The FDA approved GSK's Blujepa (gepotidacin) and Innoviva's Nuzolvence (zoliflodacin), the latter developed with GARDP, as oral treatments for uncomplicated urogenital gonorrhoea. March 2025: GSK's gepotidacin became the first new class of oral antibiotic for uncomplicated urinary tract infections in nearly three decades. February 2025: AbbVie and Pfizer's Emblaveo (aztreonam-avibactam) was approved for complicated intra-abdominal infections caused by resistant Gram-negative bacteria, following EU approval in 2024. September 2024: World leaders committed to reduce global deaths associated with antimicrobial resistance by 10% by 2030 and to improve access to antibiotics and diagnostics. September 2024: A global study estimated that antimicrobial resistance could directly cause almost 40 million deaths between 2025 and 2050 without further action. 2024: NHS England and NICE expanded their subscription payment scheme for antimicrobials, paying fixed annual fees for access to selected new antibiotics regardless of volume used. Considered in this report • Historic Year: 2020 • Base Year: 2025 • Estimated Year: 2026 • Forecast Year: 2031 Aspects covered in this report • Global Antibiotics Market with its value and forecast along with its segments • Various drivers and challenges • Ongoing trends and developments • Top profiled companies • Strategic recommendation By Drug Class • Penicillins • Cephalosporins • Carbapenems • Beta-Lactam and Beta-Lactamase Inhibitor Combinations • Macrolides • Fluoroquinolones • Tetracyclines • Other Antibiotics By Spectrum • Broad-Spectrum Antibiotics • Narrow-Spectrum Antibiotics By Indication • Respiratory Tract Infections • Urinary Tract Infections • Skin and Soft Tissue Infections • Sexually Transmitted Infections • Bloodstream Infections and Sepsis • Intra-Abdominal Infections By Distribution Channel • Hospital Pharmacies • Retail Pharmacies • Online Pharmacies • Government and Institutional Procurement

Make this report your own

Have queries/questions regarding a report

Take advantage of intelligence tailored to your business objective

Ask an Expert

Sikandar Kesari

Research Analyst

Don't pay for what you don't need. Save 30%

Customise your report by selecting specific countries or regions

Specify Scope Now